CANDESARTAN ATTENUATES DIABETIC RETINAL VASCULAR PATHOLOGY BY RESTORING GLYOXALASE-I FUNCTION

Antonia G. Miller
Genevieve Tan
Katrina J. Binger
Raelene J. Pickering
Merlin C. Thomas
Ram H. Nagaraj
Mark E. Cooper
Jennifer L. Wilkinson-Berka

1Department of Immunology, Monash University, Melbourne, Victoria, Australia, 3004
2Juvenile Diabetes Research Foundation (JDRF) Danielle Alberti Centre for Diabetic Complications, Diabetes Division, Baker International Diabetes and Heart Research Institute, Melbourne, Victoria, Australia, 3004
3Department of Ophthalmology, Case Western Reserve University, Cleveland, Ohio, USA

Address for correspondence:
Dr Antonia Miller
Email: antonia.miller@monash.edu

Submitted 20 April 2010 and accepted 8 September 2010.

Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org

This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
**Objective:** Advanced glycation end products (AGEs) and the renin-angiotensin system (RAS) are both implicated in the development of diabetic retinopathy. How these pathways interact to promote retinal vasculopathy is not fully understood. Glyoxalase-I (GLO-I) is an enzyme critical for the detoxification of AGEs and retinal vascular cell survival. We hypothesized that in retina, angiotensin II (Ang II) down-regulates GLO-I, which leads to an increase in methylglyoxal (MGO)-AGE formation. The angiotensin type 1 receptor blocker, candesartan, rectifies this imbalance and protects against retinal vasculopathy.

**Research Design and Methods:** Cultured bovine retinal endothelial cells (BREC) and bovine retinal pericytes (BRP) were incubated with Ang II (100 nM) or Ang II+candesartan (1 µM). Transgenic Ren-2 rats that overexpress the RAS were randomised to be non-diabetic, diabetic or diabetic+candesartan (5 mg/kg/day) and studied over 20 weeks. Comparisons were made with diabetic Sprague Dawley rats.

**Results:** In BREC and BRP, Ang II induced apoptosis and reduced GLO-I activity and mRNA, with a concomitant increase in nitric oxide (NO•), the latter a known negative regulator of GLO-I in BRP. In BREC and BRP, candesartan restored GLO-I and reduced NO•. Similar events occurred in vivo, with the elevated RAS of the diabetic Ren-2 rat, but not the diabetic Sprague Dawley rat, reducing retinal GLO-I. In diabetic Ren-2 rats, candesartan reduced retinal acellular capillaries, inflammation and inducible nitric oxide synthase and NO•, and restored GLO-I.

**Conclusions:** We have identified a novel mechanism by which candesartan improves diabetic retinopathy through the restoration of GLO-I.

**Chronic hyperglycaemia is the major causative factor in the pathogenesis of diabetic retinopathy (1), and may injure retinal vascular cells through a number of pathways including the enhanced production of advanced glycation end products (AGEs) (2; 3) and activation of the renin-angiotensin system (RAS) (4). In diabetes, there is an impaired glucose handling and increased glucose flux through the glycolytic pathway resulting in the accumulation of the AGE precursor, methylglyoxal (MGO), which is a source of intracellular and plasma AGEs (5). MGO can modify amine groups (such as lysine and arginine residues) resident on key cellular proteins, generating AGE-modified cellular proteins that have negative effects on protein function and gene regulation (6; 7), leading to impaired cell function. In diabetic retinopathy, MGO-derived AGEs are elevated in retina and serum and are viewed to be causative in retinal injury (8; 9). The glyoxalase system, comprised of GLO-I and GLO-II, is critical for controlling MGO levels in vivo and ultimately, MGO-AGEs. However, in diabetes, GLO-I activity is reduced in some tissues, and hence implicated in the accumulation of tissue MGO and AGEs and subsequent pathology (10; 11). Relevant to diabetic retinopathy, we reported that in retinal pericytes grown in hyperglycaemic conditions, when GLO-I function is impaired, MGO accumulates and pericyte apoptosis occurs (12).

The RAS is a major regulator of blood pressure and also contributes to retinal pathology by stimulating cell death, inflammation and angiogenesis [reviewed (4)]. The RAS is initiated by prorenin, and its
active form, renin, liberates angiotensin I from angiotensinogen. Angiotensin converting enzyme (ACE), then converts angiotensin I to angiotensin II (Ang II). Both experimental and clinical evidence indicates that angiotensin II (Ang II) blockade improves aspects of vascular and neuro-glial injury in diabetic retinopathy (13-17). Indeed, the recent findings of the DIRECT programme (DIabetic REtinopathy Candesartan Trials) indicate that angiotensin type 1 receptor blockade (AT1-RB) with candesartan, reduces the incidence of diabetic retinopathy in type 1 diabetic patients and improves the regression of retinal disease in type 2 diabetic patients (18; 19).

Despite the positive findings of DIRECT, AT1-RB did not normalise retinal pathology. This may be due to Ang II’s interactions with other pathways such as AGEs to induce organ pathology (20-23). In terms of diabetic retinopathy, the few studies that have evaluated this relationship have focussed on extracellular events where Ang II increases AGEs and the receptor for AGEs (RAGE)-induced apoptosis of retinal pericytes (24). However, there is little understanding about how intracellular AGEs, such as those generated from MGO through GLO-I inactivation, are influenced by the RAS in diabetic retinopathy. In the present study we hypothesized that Ang II stimulates the down-regulation of retinal GLO-I with a subsequent increase in MGO formation, leading to increased MGO-AGEs and vascular damage in diabetic retinopathy. We also evaluated whether candesartan’s protective effects in diabetic retinopathy involves restoration of retinal GLO-I. Studies were performed in transgenic (mRen-2)27 (Ren-2) rats, which overexpress the RAS in extra-renal tissues, are hypertensive and develop accelerated retinopathy compared to Sprague Dawley rats when made diabetic with streptozotocin (13; 15; 25). In order to more directly evaluate the relationship between Ang II and GLO-I in retinal vascular cells, studies were performed in cultured bovine retinal endothelial cells (BREC) and bovine retinal pericytes (BRP). Furthermore, given that we have identified that nitric oxide (NO*) is a regulator of GLO-I activity in retinal pericytes (12), we determined if Ang II’s modulation of retinal GLO-I is associated with changes in retinal NO*.

RESEARCH DESIGN AND METHODS

A. Tissue Culture Experiments—Culture of BREC and BRP. BREC and BRP were cultured as previously described (26). Passage numbers were between 3 to 6 for BREC, and 3 and 7 for BRP. See online appendix for details regarding treatment of cells with Ang II and candesartan.

BREC and BRP apoptosis. BRP apoptosis was quantitated by flow cytometry by double staining with annexin-FITC and propidium iodide (TACS AnnexinV-FITC Apoptosis Detection kit, R and D Systems, Minneapolis, USA) as previously described (12). BREC apoptosis was not assessed by flow cytometry, as it has been reported that the quantitation of apoptosis in BREC by this method is unreliable (27). BREC apoptosis was conducted in 96 well plates and detected by TUNEL staining using an In Situ Cell Death Detection kit (Roche Diagnostics, NSW, Australia) according to the manufacturer’s instructions. Cells were counterstained with 300nM DAPI for 1 min to visualise the nucleus. Three non-overlapping fields/well were captured using a Nikon Eclipse TE2000-U microscope coupled to a Digital Sight camera (Nikon, Melville, NY, USA) and interfaced with a computer running NIS Elements F2.20 (Nikon).

GLO-I activity and expression in BREC and BRP. To determine if Ang II influences GLO-I activity, cell lysates were prepared as previously described and 10µg of lysate assayed (12). To measure mRNA levels, 0.5µg of total RNA from either BREC or
BRP was extracted using Trizol (Invitrogen, Vic, Australia), and was DNase treated and reverse transcribed (26). Real-time PCR was conducted to detect mRNA levels of GLO-I using SYBR Green UDG Mater Mix (Invitrogen) and an ABI 7900HT Sequence Detection System (Applied Biosystems, Vic, Australia). Primers are detailed in the online appendix (Table S1).

**NO$^\bullet$ assay in BREC and BRP.** Cells were harvested and treated with nitrate reductase to reduce nitrates to nitrite as previously described (12). NO$^\bullet$ was quantitated in cells using 2,3-diaminonaphthalene (28). See online appendix for further detail.

**B. Animal Studies—Procedures complied with the National Health and Medical Research Council of Australia’s (NHMRC) Code of the Care and Use of Animals for Scientific Purposes and were approved by the Alfred Medical Research and Education Precinct’s (AMREP) Animal Ethics Committee. Female 8-week-old Ren-2 rats were obtained from AMREP Animal Services Pty. Ltd. Female 8-week-old Sprague Dawley rats were obtained from the Animal Research Centre (Perth, WA, Australia) and served as age-matched controls for Ren-2 rat studies. All rats had free access to normal rat chow and drinking water. They were housed in a stable environment maintained at 22°C±1°C (12 hour light–dark cycle). Ren-2 rats were randomised to the following groups, (1) non-diabetic control, (2) diabetic control, and (3) diabetic+candesartan (5mg/kg/day, gavage). To become diabetic, rats were fasted overnight and given a single tail vein injection of streptozotocin (50mg/kg, 0.1M citrate buffer; Sigma-Aldrich)(13; 15; 25). Two to three days later, rats began treatment with candesartan for 4 or 20 weeks. Diabetic rats received insulin (Humulin, Eli Lilly Co., USA, 2 units) every 2 days by subcutaneous injection. Body weight was measured each month. Systolic blood pressure was measured each month using a tail cuff method (AD Instruments, Colorado Springs, CO, USA)(13; 15; 25). Blood glucose was determined using Accu-check Advantage II Glucose Meter (Roche, Grenzacherstrasse, Basel, Switzerland). Prior to tissue collection, rats were anaesthetised with Nembutal (60mg/kg, Sigma-Aldrich).

**Retinal pathology.** Acellular capillaries and leukocyte adherence in large retinal vessels were measured as previously described (13; 26). See the online appendix for further detail.

**Real-time PCR in retina.** Retinal mRNA levels were determined by real-time PCR as previously described (26). One µg of total RNA extracted from retina was DNase-treated and reverse transcribed. mRNA levels of vascular endothelial growth factor (VEGF), intercellular adhesion molecule-1 (ICAM-I), tumour necrosis factor-alpha (TNF-α), GLO-I and inducible nitric oxide synthase (iNOS) were measured. See online appendix for descriptions of primers (Table S1).

**Retinal GLO-I activity, tissue and plasma MGO-AGE, argpyrimidine and NO$^\bullet$ levels.** For GLO-I activity, flash-frozen whole retina was prepared as described in the online appendix and 10 µg of retina was assayed as described for BREC and BRP. Tissue MGO-AGE and argpyrimidine, a specific MGO-AGE, were detected in undialyzed retinal lysates generated for the GLO-I assay by direct ELISA. See online appendix for further detail. Plasma MGO-AGEs and total AGEs (all AGEs including MGO-AGEs) were quantitated by competitive ELSA. See online appendix for further detail. NO$^\bullet$ was measured in retinal lysates as described in (28). See online appendix for further detail.

**Statistics.** For all cell culture studies, experiments were performed in triplicate and then the entire experiment independently repeated at least three times. Data were analysed using either SPSS v11 (SPSS Inc., Chicago, IL, USA) or GraphPad Prism 5 (GraphPad Software Inc, La Jolla, CA, USA). For animal experiments, at least 6 rats were
required in each group to achieve statistical significance. To determine how many animals per group were required, we compared previous experimental data in diabetic animals with treated groups for each respective end-point, and then calculated the number of animals required to achieve an expected power of 0.8 (80%) and a P value of 0.05. Both animal and cell culture datasets were assessed for normality and in the case of greater than 2 treatments either one-way ANOVA (parametric), followed by appropriate post-hoc analyses correcting for the number of comparisons, or, Kruskal-Wallis tests followed by individual Mann-Whitney U tests (non-parametric) were conducted. Where only 2 treatments were given, either an unpaired t-test (parametric) or a Mann Whitney U test (non-parametric) was conducted. Investigators were masked to the groups. A value of P < 0.05 was considered significant.

RESULTS

Ang II stimulates apoptosis and decreases GLO-I in BREC and BRPs. To determine if Ang II induces apoptosis in retinal vascular cells, BREC and BRP were incubated with 100 nM Ang II for 24 hours. In BREC and BRP, Ang II treatment resulted in a 500 and 30% increase in either TUNEL or Annexin-positive cells respectively compared to control (Figure 1). Given this finding we next evaluated GLO-I in BREC and BRP and found that in both cell types, Ang II decreased GLO-I activity and mRNA by 20% compared to controls (Figure 2). To confirm the involvement of Ang II in the down-regulation of GLO-I, we next measured GLO-I following treatment with the AT1-RB, candesartan. In both BREC and BRP, candesartan restored both GLO-I activity and mRNA to control levels in Ang II treated cells (Figure 2), and in the case of BREC, GLO-I mRNA was elevated above control levels (Figure 2). Overall, BREC was more responsive to the actions of candesartan in terms of restoration of GLO-I function. Candesartan in the absence of Ang II, in almost all instances, did not influence GLO-I levels (See online appendix Supplemental Figure 1 in the online appendix available at http://diabetes.diabetesjournals.org).

Ang II’s reduction of GLO-I and in BRP is accompanied by an increase in NO•. To determine if Ang II’s down-regulation of GLO-I involves NO•, we measured NO• production in BREC and BRP following Ang II treatment in the presence or absence of candesartan. In BREC, Ang II had no effect on NO• levels, while in BRP, Ang II increased NO• production 1.2-fold. In both cell types, candesartan reduced NO• levels in Ang II-treated cells compared to those only receiving Ang II (Figure 3).

Diabetic Ren-2 rats develop acellular capillaries and increased retinal leukostasis which is reduced with candesartan. The in vivo counterpart of BREC and BRP apoptosis is the formation of acellular capillaries. To determine if GLO-I expression is reduced in retina from diabetic Ren-2 rats and correlates with acellular capillary formation, we first evaluated the number of acellular capillaries in retina of Ren-2 rats after 20 weeks of diabetes. Acellular capillary formation was increased in the mid and peripheral retina of diabetic Ren-2 rats compared to non-diabetic controls and reduced with candesartan (Figure 4). As leukocyte adherence in retinal vessels may precede the development of acellular capillaries, both 4 and 20-week time points were examined. In diabetic Ren-2 rats, adherent leukocytes were increased after 4 and 20 weeks of diabetes compared to non-diabetic controls (Figure 5), with leukocyte adherence most pronounced in the 4 week diabetic group. In diabetic Ren-2 rats, candesartan reduced the increase in leukocyte adherence in retinal vessels to control levels or below (Figure 5).
Gene expression of VEGF, inflammatory factors and iNOS in retina of diabetic Ren-2 rats. In diabetic Ren-2 rats, the level of retinal ICAM-1 and TNF-α mRNA doubled, and VEGF mRNA increased by 0.5 fold compared to non-diabetic controls. In diabetic Ren-2 rats, both ICAM-1 and VEGF mRNA levels in retina were reduced with candesartan to the level of non-diabetic controls (Figure 6) and TNF-α mRNA to below non-diabetic control levels. (Figure 6). In diabetic Ren-2 rats, the level of retinal iNOS mRNA was increased by 0.3 fold compared to non-diabetic controls, and candesartan reduced retinal iNOS mRNA levels to below the level of non-diabetic controls (Figure 6).

Retinal pathology in diabetic Ren-2 rats is associated with a reduction in retinal GLO-I. In Ren-2 rats, the retinal pathology that occurred at 4 and 20 weeks of diabetes was accompanied by modulations in GLO-I function. A decrease in retinal GLO-I activity was observed at 4 weeks of diabetes, although changes in mRNA levels were not detected (Figure 7 and online appendix Supplemental Figure 2 respectively). However, after 20 weeks of diabetes, retinal GLO-I mRNA was decreased (Figure 7). Candesartan increased GLO-I expression in the retina of diabetic Ren-2 rats, which is consistent with our findings in BREC and BRP. In order to determine if the reduction in retinal GLO-I in diabetic Ren-2 rats is related to the overexpression of the RAS in these animals, comparisons were made to non-diabetic and diabetic Sprague Dawley rats with a suppressed RAS (Figure 7). The expression of GLO-I in retina from non-diabetic Sprague Dawley rats was unchanged with diabetes. We then investigated whether GLO-I dysregulation by the RAS increased MGO-derived AGEs. After 4 weeks of diabetes in Ren-2 rats, MGO-AGE levels in retina were increased. In diabetic Ren-2 rats, candesartan tended to reduce the increase in retinal MGO-AGE but this was not significant (Figure 7).

The specific MGO-AGE, argyprimidine, was also measured in retina, and was unchanged with diabetes in the Ren-2 rat; however, candesartan did reduce the levels of retinal argyprimidine compared to controls (Figure 7). After 20 weeks of diabetes, both plasma MGO-AGEs and total AGEs were elevated in diabetes and significantly reduced with candesartan (Figure 7). Retinal NO was significantly suppressed in the diabetic Ren-2 rats treated with candesartan compared to both diabetic and non-diabetic controls (Figure 7).

Body weight, blood glucose and systolic blood pressure. The results are found in the online appendix in Table S2.

DISCUSSION

The present study provides novel evidence that GLO-I, an enzyme critical for retinal vascular cell survival (12), is down-regulated by Ang II in the retina. Our findings are supported by evidence that the AT1-RB, candesartan, improves acellular capillary formation and inflammation in diabetic retinopathy with a concomitant restoration of retinal GLO-I expression and a reduction of MGO-AGEs and in particular, the specific MGO-AGE argpyrimidine. These findings broaden the known actions of Ang II in the AGE pathway to include not only extracellular AGE-related events such as RAGE-mediated cellular apoptosis (24; 29; 30), but also the intracellular formation of MGO-AGEs. In terms of the mechanism by which retinal GLO-I is regulated, our previous study in retinal pericytes indicated a role for NO• (12). We now extend this finding to report that in retinal vascular cells, candesartan reduces NO• levels, which is accompanied by the restoration of GLO-I. Overall, the present study provides new information about how Ang II interacts with the AGE pathway and the cellular mechanisms by which candesartan exerts its
potent protective effects in diabetic retinopathy (Figure 8).
At 20 weeks of diabetes, we observed increased acellular capillary formation in the mid and peripheral retina of the Ren-2 rat, which is consistent with our previous studies in the Ren-2 rat (13) and observed in diabetic patients (31). Acellular capillary formation is a pathology that occurs in retinal microvessels following the apoptosis of both endothelial cells and pericytes (32). These events may result in areas of retinal non-perfusion, which are viewed to lead to the up-regulation of angiogenic growth factors such as VEGF with subsequent pathological angiogenesis. The mechanisms responsible for retinal vascular cell apoptosis are not fully defined; however, previous studies by our group indicate that GLO-I is necessary for the survival of human retinal pericytes (12). The present study builds on this information by identifying in retinal vascular cells that Ang II is a novel, negative regulator of GLO-I activity and expression and inducer of cellular apoptosis. Supporting an interaction between Ang II and GLO-I is our finding that in diabetic Ren-2 rats with an enhanced extra-renal RAS in tissues including the eye (15), retinal GLO-I expression is reduced with a concomitant increase in acellular capillaries. It is noteworthy that in age-matched diabetic Sprague Dawley rats, retinal GLO-I is not reduced and that these animals do not develop acellular capillaries (13). We acknowledge that GLO-I activity was not measured in long-term diabetes when acellular capillaries appear, nevertheless, GLO-I activity was reduced in the early stages of diabetic retinopathy when inflammation is maximal. The ability of candesartan to restore retinal GLO-I and attenuate retinal vasculopathy including inflammation, which is viewed to contribute to diabetic retinopathy (33), may be important when considering the underlying mechanisms by which Ang II blockers such as candesartan provide retinoprotection. Although the glyoxalase system is a critical regulator of the AGE pathway, it is the formation of MGO-AGEs that are implicated in cellular damage. To date, the majority of studies in this area have focused on the contribution of AGEs via RAGE to AGE-mediated pathology, including in diabetic retinopathy (34). However, AGEs may not be the primary RAGE ligands in vivo, given that proteins must be heavily glycated before the can bind to RAGE, and this extensive glycation may not occur to a major extent in vivo (35). There are limited reports detailing the contribution of intracellular AGEs to pathology, although there is increasing evidence to support this possibility (36; 37). Another dimension to the RAGE paradigm is the recent finding that GLO-I can control the expression of RAGE and its ligands by modulating the levels of MGO (38), consistent with the view that intracellular glycation can control RAGE expression. The influence of the RAS on AGE formation has been established in the diabetic nephropathy (20-23), with in general a focus on RAGE-mediated signalling. This is true also for the limited studies in diabetic retinopathy, where Ang II mediates increases in RAGE and AGE-induced apoptosis of retinal pericytes (24; 29; 30). In the present study, an evaluation of intracellular MGO-AGE formation, as detected by ELISA using an antibody raised against a heterogeneous mixture of MGO-AGEs, revealed an increased in retina from diabetic Ren-2 rats. A specific MGO-AGE, argpyrimidine, formed on reaction of MGO with arginine residues, was also examined, given the known preferential modification of arginine over lysine (39), and the previous detection of this specific moiety in the diabetic kidney (39; 40). However, despite an elevation in retinal MGO-AGEs in diabetic Ren-2 rats, argpyrimidine was not increased, a finding which may be explained by its presence in lower quantities relative to other MGO-AGEs.
Further evidence that Ang II influences retinal MGO-AGEs arises from our finding that candesartan which restored GLO-I in diabetic Ren-2 retina, also reduced retinal MGO-AGEs and argpyrimidine levels. These results are consistent with a previous study, which reported that candesartan reduced immunolabelling of the AGE pentosidine in the retina of diabetic rats, although in that study pentosidine levels were not specifically quantitated (42). Consistent with candesartan’s reduction of retinal MGO-AGEs, candesartan lowered plasma MGO-AGE and it is noteworthy that the majority of AGES detected in plasma using our assay were MGO-derived. Overall, our findings establish a mechanism for the observed regulation of AGES by the RAS in diabetic retinopathy that may be indeed relevant to other diabetic complications (20-23).

A possible candidate for Ang II’s downregulation of GLO-I in the retina is via an increase in NO\(^\bullet\). This postulate is based on our previous studies in human retinal pericytes which indicated that GLO-I is regulated at the transcriptional level by NO\(^\bullet\) (12). Furthermore, there is considerable evidence that Ang II stimulates NO\(^\bullet\) production, which leads to vascular pathology (43), including retinal inflammation and breakdown of the blood retinal barrier (44; 45). In the present study, although Ang II reduced GLO-I activity and expression in both cultured retinal endothelial cells and pericytes, it only increased NO\(^\bullet\) levels in retinal pericytes. The reasons for Ang II not stimulating NO\(^\bullet\) in retinal endothelial cells is not clear, however, our data would indicate that Ang II via the AT1-R influences NO\(^\bullet\) production in retinal endothelial cells, with candesartan reducing NO\(^\bullet\) levels in both cell populations. Similarly, in Ren-2 retina, NO\(^\bullet\) levels were not significantly elevated with diabetes, however, candesartan reduced NO\(^\bullet\) levels below non-diabetic control, supporting the idea that in retina Ang II influences NO\(^\bullet\) production via the AT1-R. A consideration when interpreting our results is that physiological levels of NO\(^\bullet\) are required for normal tissue function and can inhibit leukocyte adhesion (46) and mediate vasorelaxation (47). Our finding that candesartan reduced retinal iNOS and NO\(^\bullet\) below control levels, may indicate that further studies are required to determine whether lower doses of AT1-RB can maintain NO\(^\bullet\) at physiological levels within the retina with a concomitant reduction in retinal pathology and restoration of GLO-I. In terms of a pathological role for the NO\(^\bullet\) system in diabetic retinopathy, our findings are consistent with previous studies where iNOS is implicated as a major contributor to the increased NO\(^\bullet\) levels in diabetic retinopathy (48; 49) and reports that tissue iNOS can be reduced with candesartan (22).

A possible limitation of the present study is that the effectiveness of candesartan on diabetic retinopathy in the Ren-2 rat could be due to a reduction of the hypertension of this animal rather than inhibition of the growth factor effects of angiotensin II. However, in our previous studies, a comparison of age- and blood pressure-matched diabetic spontaneously hypertensive rats to diabetic Ren-2 rats, revealed that the former did not develop as severe diabetic retinopathy, suggesting that the overexpression of the RAS in the Ren-2 rat was largely responsible for the development of diabetic retinopathy in this model (15). Furthermore, in diabetic Ren-2 rats, the \(\beta\)-blocker, atenolol, and the AT1-RB, valsartan, both produced similar reductions in systolic blood pressure; however, only valsartan attenuated retinal acellular capillary formation and the decline in retinal function (13; 14). Nonetheless, whether hypertension per se influences retinal GLO-I activity and expression in diabetes is to our knowledge unknown, and warrants investigation in future studies.
In conclusion, the results from the current study are timely, given the positive findings from recent clinical trials, which indicate that AT1-RB and ACE inhibition confer protective effects on the retinal vasculature in diabetic retinopathy (18; 19; 50). Our data suggest that GLO-I could be a key enzyme that bridges the RAS and AGE pathways, thereby contributing to the development of diabetic retinopathy (Figure 8). These findings enhance our understanding of how RAS blockers such as candesartan act at the molecular level to confer retinal vascular protection in disorders such as diabetes.

**Author Contributions.** AGM designed and conducted experiments, analysed data and prepared the manuscript; GT conducted experiments and analysed data; KJB conducted experiments, analysed data and reviewed manuscript; RP designed and performed plasma ELISA; MT designed plasma ELISA experiments and contributed to discussion; RHN provided advice for some experiments and reviewed manuscript; JWB designed experiments, assisted with discussion and preparation of the manuscript.

**ACKNOWLEDGEMENTS**

We thank Kylie McMaster, Department of Immunology, Monash University for excellent technical assistance. Thank-you to Dr Mike Griffin of Bio21, University of Melbourne for access to equipment to conduct the GLO-I activity experiments. Antonia Miller is a Juvenile Diabetes Research Foundation Post-doctoral Fellow. Jennifer Wilkinson-Berka is a National Health and Medical Research Council (NHMRC) of Australia, Senior Research Fellow. Mark Cooper is a NHMRC Australia Fellow and a Juvenile Diabetes Research Foundation Scholar. Merlin Thomas is supported by Kidney Health Australia (Bootle Award). This study was funded by a Diabetes Australia Research Trust and an Eli Lilly New Investigator grants awarded to Antonia Miller, and Astra Zeneca (Mölndal, Sweden). NIH grants to Ram Nagaraj (R01EY-016219 and R01EY-09912).

**REFERENCES**


34. Glenn JV, Stitt AW: The role of advanced glycation end products in retinal ageing and disease. *Biochim Biophys Acta* 1790:1109-1116, 2009
35. Thornalley PJ: Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE)--an introduction. *Mol Nutr Food Res* 51:1107-1110, 2007


38. Yao D, Brownlee M: Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. *Diabetes* 59:249-255, 2010


**Figure 1:** BREC and BRP apoptosis as detected by TUNEL staining and flow cytometry respectively, following treatment with Ang II. In BREC, TUNEL staining is increased following treatment with 100 nM Ang II for 24 hours (A) compared to control (C). DAPI nuclear staining of Ang II treated (B) and control (D) BREC. Arrows denote TUNEL positive BREC, and arrowhead denotes cellular blebbing, a common feature of apoptosis. Magnification=200x. Representative example of Annexin V-FITC (x axis) and propidium iodide (PI) staining (y axis) to detect apoptotic cells following treatment of BRP with 100 nM Ang II (E) or control (F) for 24 hours. Increases were observed in the Annexin V positive, or early apoptotic phase (bottom right hand quadrant), and Annexin V positive/PI positive (top right hand quadrant), or late apoptotic phase (E). Bottom left quadrant, viable cells; Top left quadrant, necrotic cells (PI staining only). FITC, fluoroisothiocyanate. G, Graphical representation of BREC apoptosis detected by TUNEL staining; *P<0.01 vs control. N=3 samples, and is a representative dataset of 3 independent experiments. H, Graphical representation of BRP apoptosis detected by Annexin/PI staining; *P<0.03 vs control. All data were analysed by unpaired t-tests. N=3 independent experiments. Values are mean±sem.
Figure 2: GLO-I mRNA and activity levels in BREC and BRP following treatment with Ang II and candesartan. In BREC (A, B) and BRP (C, D), GLO-I mRNA (A, C) and activity (B, D) is decreased following treatment with Ang II (100 nM) for 24 hours compared to control. Candesartan (Cand, 1 µM) restored GLO-I activity and mRNA in BREC and BRP co-incubated with Ang II. A, B * P<0.05 vs control, †P<0.05 vs Ang II. C, D * P<0.03 vs control. All data were analyzed by Krukal-Wallis test, followed by Mann Whitney U tests. Values are the mean of N=3-4 independent experiments with triplicate samples within each experiment.

Figure 3: NO• levels in BREC (A) and BRP (B) following treatment with Ang II and candesartan for 24 hours. (A), Treatment of BREC with 100 nM Ang II had no effect on NO• levels. In BREC treated with Ang II+candesartan (Cand, 1 µM), NO• levels were reduced below both control and Ang II treated cells. *P<0.01 vs control, †P<0.03 vs Ang II. (B) Treatment of BRP with 100 nM Ang II significantly increased NO• levels. In BRP treated with Ang II+Cand, NO• levels were reduced to control levels. *P<0.05 vs control, †P<0.05 vs Ang II. BRP were analyzed by one-way ANOVA, followed by Bonferroni post-hoc tests. BREC were analyzed by Kruskal-Wallis tests followed by Mann-Whitney U tests. Values are the mean of 3 and 7 independent experiments (BRP and BREC respectively) with triplicate samples within each experiment.
Figure 4: Acellular capillaries in trypsin digests of retina in representative micrographs from Ren-2 rats after 20 weeks of diabetes. Retina stained with Periodic-acid Schiff’s reagent. Scale bar=20 µm. Non-diabetic (A), diabetic (B), and diabetic+candesartan (Cand, 5mg/kg/day) (C). In diabetic Ren-2 rats, acellular capillaries were increased in the mid and peripheral retina compared to non-diabetic Ren-2 rats. In diabetic Ren-2 rats, candesartan reduced acellular capillaries in the mid and peripheral retina to the level of non-diabetic control. Arrow denotes acellular capillary with pericyte ghost at arrowhead tip. Graphs showing number of acellular capillaries per retinal field (mean±sem) in the central (D), mid (E) and peripheral (F) retina *P<0.05 vs non-diabetic, diabetic+Cand. N=8 animals/group. Data were analyzed by one-way ANOVA, followed by Bonferroni post-hoc tests.
**Figure 5:** Leukocyte adherence in retinal blood vessels in representative micrographs of Ren-2 rats after 4 and 20 weeks of diabetes following perfusion with rhodamine-coupled to Concanavalin A. Scale bar=80 μm. Arrows denote adherent leukocytes. Leukocytes were counted in all retinal vessels. Four week study: Non-diabetic (A), diabetic (B), and diabetic+candesartan (Cand) (C). Twenty week study: Non-diabetic (D), diabetic (E) and diabetic+candesartan (Cand) (F). Diabetes at both 4 and 20 weeks is associated with an increase in leukocyte adherence in retinal vessels compared to age-matched non-diabetic control. In diabetic Ren-2 rats, candesartan reduced leukocyte adherence in retinal vessels to the level of non-diabetic control. **G,** graphical representation of leukocyte adherence in vessels of the retina (mean±sem). N=6-10 animals/group. *P<0.03 vs age-matched non-diabetic control and diabetic+Cand; †P<0.02 vs week 4 diabetic; ‡P<0.005 vs age-matched non-diabetic control. BREC were analyzed by Kruskal-Wallis tests followed by Mann-Whitney U tests.
Figure 6: ICAM-1 (A), VEGF (B), TNF-α (C), and iNOS (D) mRNA levels in retina of Ren-2 rats after 4 weeks of diabetes. Retinal ICAM-1, VEGF, TNF-α and iNOS mRNA levels are increased in diabetic Ren-2 rats compared to non-diabetic control. In diabetic Ren-2 rats, candesartan (Cand) reduced both retinal ICAM-1 (A), and VEGF mRNA (B) to the level of non-diabetic controls, with TNF-α (C), and iNOS mRNA (D), decreasing to below control levels. For figures A, B and D, data were analyzed by one-way ANOVA, followed by Bonferroni post-hoc tests. *P<0.05 vs non-diabetic control. †P<0.05 vs diabetic control. For figure C, data was analyzed by Krsukal-Wallis tests followed by Mann-Whitney U tests. *P<0.02 vs non-diabetic control. †P<0.0001 vs diabetic control. N=8-13 animals/group. Values are mean±sem.

Figure 7: GLO-I activity and mRNA, and MGO-AGE levels in diabetic Ren-2 rats. In Ren-2 rats after 4 weeks of diabetes, retinal GLO-I activity (A) is reduced compared to non-diabetic control, and tends to be restored with candesartan, although this is not significant (*P<0.03 vs non-diabetic Ren-2 control). In Ren-2 rats after 20 weeks of diabetes, retinal GLO-I mRNA (B) is clearly reduced compared to non-diabetic control, and is restored to control levels with candesartan (*P<0.005 vs non-diabetic control, †P<0.05 vs diabetic Ren-2 control). In comparison, in Sprague Dawley (SD) rats (B), no changes in retinal GLO-I mRNA are observed with 20 weeks of diabetes. In Ren-2 rats after 4 weeks of diabetes, the reduction in retinal GLO-I activity (A) is accompanied by an increase in the levels of retinal MGO-AGE (C), (*P<0.01 vs non-diabetic Ren-2 control). In diabetic Ren-2 rats, candesartan tends to decrease the levels of retinal MGO-AGE, but this is not significant. In diabetic Ren-2 rats at 4 weeks, the levels in retina of the specific MGO-AGE, argpyrimidine (D) and NO• levels (E), are unchanged compared to non-diabetic controls; however, candesartan reduced retinal argpyrimidine (*P<0.05 vs non-diabetic Ren-2 control, †P<0.01 vs diabetic Ren-2 control) and NO• levels (*P<0.05 vs non-diabetic Ren-2 control. †P<0.01 vs diabetic Ren-2 control). F, Plasma MGO-AGEs (black bars) are
increased in Ren-2 rats after 20 weeks of diabetes compared to non-diabetic controls, and are reduced with candesartan (Cand) to non-diabetic levels (*P<0.05 vs non-diabetic Ren-2 control; †P<0.05 vs. diabetic Ren-2 control). Other AGEs (non-MGO AGEs, white bars) and total AGEs (MGO-AGE + other AGEs, black + white bars) were increased in Ren-2 rats after 20 weeks of diabetes and reduced with Cand to non-diabetic control levels (‡P<0.005 vs “other AGE” non-diabetic Ren-2 control; §P<0.04 vs. “other AGE” diabetic Ren-2 control; #P<0.02 vs “total AGE” non-diabetic Ren-2 control; **P<0.02 vs. “total AGE” diabetic Ren-2 control). N=5-8 animals/group. Values are mean±sem. Data in Figures C and D were analyzed by one-way ANOVA, followed by Bonferroni post-hoc tests. All other datasets in this figure were analyzed by Kruskal-Wallis tests, followed by Mann Whitney U tests.
**Figure 8.** Proposed mechanism by which Ang II down-regulates GLO-I in retinal vascular cells leading to the generation of AGEs and vascular injury. The AT1-RB, candesartan, is able to prevent diabetic retinal vascular injury by reducing nitric oxide and restoring GLO-I levels.

![Diagram of proposed mechanism]

**REFERENCES**

34. Glenn JV, Stitt AW: The role of advanced glycation end products in retinal ageing and disease. *Biochim Biophys Acta* 1790:1109-1116, 2009
35. Thornalley PJ: Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE)--an introduction. *Mol Nutr Food Res* 51:1107-1110, 2007
38. Yao D, Brownlee M: Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. *Diabetes* 59:249-255, 2010


